Choroidal Neovascularization Associated with Multiple Evanescent White Dot Syndrome Treated with Intravitreal Ranibizumab

Maurizio Battaglia Parodi, Pierluigi Iacono, Ilaria Zucchiatti, Francesco Bandello

Research output: Contribution to journalArticle

Abstract

Purpose: To describe the clinical outcomes of intravitreal ranibizumab treatment for subfoveal choroidal neovascularization (CNV) associated with multiple evanescent white dot syndrome (MEWDS). Methods: This is a prospective, interventional, case series. All recruited patients underwent a baseline intravitreal ranibizumab injection and were monitored monthly over a 12-month follow-up, following a pro-re-nata regimen. Results: Four patients (four eyes) were included in the study. Mean best-corrected visual acuity (BCVA) changed from 0.60 ± 0.20 at baseline to 0.07 ± 0.05 logMAR at 12-month examination. Baseline central macular thickness reduced from 330 ± 32 µm to the final value of 228 ± 14 µm at the 1-year follow-up. Overall, a mean number of 2.2 ranibizumab injections were administered at the end of 12 months. Conclusions: Intravitreal ranibizumab treatment represents a valuable therapeutic option for the management of CNV associated with MEWDS.

Original languageEnglish
Pages (from-to)1-4
Number of pages4
JournalOcular Immunology and Inflammation
DOIs
Publication statusE-pub ahead of print - Nov 30 2016

Fingerprint

Choroidal Neovascularization
Intravitreal Injections
Visual Acuity
Therapeutics
Injections
Ranibizumab

Keywords

  • Choroidal neovascularization
  • multiple evanescent white dot syndrome
  • ranibizumab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Ophthalmology

Cite this

@article{8a22edc15d1742ffb5fb8fb030258d6c,
title = "Choroidal Neovascularization Associated with Multiple Evanescent White Dot Syndrome Treated with Intravitreal Ranibizumab",
abstract = "Purpose: To describe the clinical outcomes of intravitreal ranibizumab treatment for subfoveal choroidal neovascularization (CNV) associated with multiple evanescent white dot syndrome (MEWDS). Methods: This is a prospective, interventional, case series. All recruited patients underwent a baseline intravitreal ranibizumab injection and were monitored monthly over a 12-month follow-up, following a pro-re-nata regimen. Results: Four patients (four eyes) were included in the study. Mean best-corrected visual acuity (BCVA) changed from 0.60 ± 0.20 at baseline to 0.07 ± 0.05 logMAR at 12-month examination. Baseline central macular thickness reduced from 330 ± 32 µm to the final value of 228 ± 14 µm at the 1-year follow-up. Overall, a mean number of 2.2 ranibizumab injections were administered at the end of 12 months. Conclusions: Intravitreal ranibizumab treatment represents a valuable therapeutic option for the management of CNV associated with MEWDS.",
keywords = "Choroidal neovascularization, multiple evanescent white dot syndrome, ranibizumab",
author = "{Battaglia Parodi}, Maurizio and Pierluigi Iacono and Ilaria Zucchiatti and Francesco Bandello",
year = "2016",
month = "11",
day = "30",
doi = "10.1080/09273948.2016.1247175",
language = "English",
pages = "1--4",
journal = "Ocular Immunology and Inflammation",
issn = "0927-3948",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Choroidal Neovascularization Associated with Multiple Evanescent White Dot Syndrome Treated with Intravitreal Ranibizumab

AU - Battaglia Parodi, Maurizio

AU - Iacono, Pierluigi

AU - Zucchiatti, Ilaria

AU - Bandello, Francesco

PY - 2016/11/30

Y1 - 2016/11/30

N2 - Purpose: To describe the clinical outcomes of intravitreal ranibizumab treatment for subfoveal choroidal neovascularization (CNV) associated with multiple evanescent white dot syndrome (MEWDS). Methods: This is a prospective, interventional, case series. All recruited patients underwent a baseline intravitreal ranibizumab injection and were monitored monthly over a 12-month follow-up, following a pro-re-nata regimen. Results: Four patients (four eyes) were included in the study. Mean best-corrected visual acuity (BCVA) changed from 0.60 ± 0.20 at baseline to 0.07 ± 0.05 logMAR at 12-month examination. Baseline central macular thickness reduced from 330 ± 32 µm to the final value of 228 ± 14 µm at the 1-year follow-up. Overall, a mean number of 2.2 ranibizumab injections were administered at the end of 12 months. Conclusions: Intravitreal ranibizumab treatment represents a valuable therapeutic option for the management of CNV associated with MEWDS.

AB - Purpose: To describe the clinical outcomes of intravitreal ranibizumab treatment for subfoveal choroidal neovascularization (CNV) associated with multiple evanescent white dot syndrome (MEWDS). Methods: This is a prospective, interventional, case series. All recruited patients underwent a baseline intravitreal ranibizumab injection and were monitored monthly over a 12-month follow-up, following a pro-re-nata regimen. Results: Four patients (four eyes) were included in the study. Mean best-corrected visual acuity (BCVA) changed from 0.60 ± 0.20 at baseline to 0.07 ± 0.05 logMAR at 12-month examination. Baseline central macular thickness reduced from 330 ± 32 µm to the final value of 228 ± 14 µm at the 1-year follow-up. Overall, a mean number of 2.2 ranibizumab injections were administered at the end of 12 months. Conclusions: Intravitreal ranibizumab treatment represents a valuable therapeutic option for the management of CNV associated with MEWDS.

KW - Choroidal neovascularization

KW - multiple evanescent white dot syndrome

KW - ranibizumab

UR - http://www.scopus.com/inward/record.url?scp=84997766143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84997766143&partnerID=8YFLogxK

U2 - 10.1080/09273948.2016.1247175

DO - 10.1080/09273948.2016.1247175

M3 - Article

SP - 1

EP - 4

JO - Ocular Immunology and Inflammation

JF - Ocular Immunology and Inflammation

SN - 0927-3948

ER -